Sidewinder Therapeutics has raised $137 million in an oversubscribed Series B financing round, signaling strong investor confidence in its next-generation cancer treatment platform based on bispecific antibody-drug conjugates (ADCs).
The funding round was co-led by Frazier Life Sciences and Novartis Venture Fund, with participation from existing investor OrbiMed and several new backers. These include Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund, Astellas Venture Management, and Alexandria Venture Investments.
Alongside the financing, several key investors have joined the company’s board of directors, reflecting their active role in shaping Sidewinder’s strategic direction. New board members include representatives from Frazier Life Sciences, Novartis Venture Fund, Goldman Sachs Alternatives, and DCVC Bio.
Sidewinder Therapeutics is focused on advancing bispecific ADCs, a cutting-edge class of cancer therapies designed to improve the precision and effectiveness of drug delivery. Unlike traditional ADCs, which target a single antigen, bispecific ADCs are engineered to bind to two different targets simultaneously. This approach enhances the ability to selectively identify and attack cancer cells while minimizing damage to healthy tissue.
The company’s proprietary platform centers on targeting receptor co-complexes that are highly expressed on certain solid tumors. By designing antibodies that bind both an oncogenic driver receptor and an internalizing receptor, Sidewinder aims to improve drug uptake into tumor cells and increase therapeutic efficacy. This dual-targeting mechanism is expected to address longstanding challenges in the ADC field, particularly around safety and specificity.
Sidewinder’s pipeline is focused on cancers with limited treatment options and large patient populations, including squamous cell carcinomas of the lung, head and neck cancers, and gastrointestinal cancers such as colorectal cancer. The company plans to advance its lead candidate into clinical development by 2027.
Chief Executive Officer Eric Murphy emphasized that the ADC field is at a critical turning point, driven by recent technological advances that enable more sophisticated drug designs. He noted that the company intends to play a leading role in this next wave of innovation.
Investors echoed this optimism, highlighting the company’s differentiated scientific approach and its potential to overcome key limitations of existing therapies. With fresh capital and strategic backing, Sidewinder is positioning itself to help redefine treatment options for patients with hard-to-treat cancers.
The financing reflects a broader trend of increased investment in next-generation oncology platforms, as the industry seeks more targeted and effective therapies to improve patient outcomes.